Metastatic Renal Cell Carcinoma: Sunitinib as First-Line Treatment; Results of a Retrospective Study
Background: Targeted agents were introduced over past years because of better understanding of oncogenetic mechanisms in metastatic renal cell carcinoma (mRCC). These agents include tyrosine kinase inhibitors (TKIs) such as sorafenib, sunitinib, pazopanib and axitinib.
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sciendo
2015-12-01
|
| Series: | Forum of Clinical Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1515/fco-2015-0017 |
| _version_ | 1818191881180282880 |
|---|---|
| author | El-Hadaad Hend Ahmed Wahba Hanan Ahmed Abd-El Hay Ghazy Hayam Fathy |
| author_facet | El-Hadaad Hend Ahmed Wahba Hanan Ahmed Abd-El Hay Ghazy Hayam Fathy |
| author_sort | El-Hadaad Hend Ahmed |
| collection | DOAJ |
| description | Background: Targeted agents were introduced over past years because of better understanding of oncogenetic mechanisms in metastatic renal cell carcinoma (mRCC). These agents include tyrosine kinase inhibitors (TKIs) such as sorafenib, sunitinib, pazopanib and axitinib. |
| first_indexed | 2024-12-12T00:21:39Z |
| format | Article |
| id | doaj.art-5d5d39e52d0c4a29a366c0d56ac157fa |
| institution | Directory Open Access Journal |
| issn | 1792-362X |
| language | English |
| last_indexed | 2024-12-12T00:21:39Z |
| publishDate | 2015-12-01 |
| publisher | Sciendo |
| record_format | Article |
| series | Forum of Clinical Oncology |
| spelling | doaj.art-5d5d39e52d0c4a29a366c0d56ac157fa2022-12-22T00:44:43ZengSciendoForum of Clinical Oncology1792-362X2015-12-0164232710.1515/fco-2015-0017fco-2015-0017Metastatic Renal Cell Carcinoma: Sunitinib as First-Line Treatment; Results of a Retrospective StudyEl-Hadaad Hend Ahmed0Wahba Hanan Ahmed1Abd-El Hay Ghazy Hayam Fathy2Clinical Oncology and Nuclear Medicine department, Faculty of Medicine, Mansoura University, EgyptClinical Oncology and Nuclear Medicine department, Faculty of Medicine, Mansoura University, EgyptMedical Oncology department, Faculty of Medicine, Mansoura University, EgyptBackground: Targeted agents were introduced over past years because of better understanding of oncogenetic mechanisms in metastatic renal cell carcinoma (mRCC). These agents include tyrosine kinase inhibitors (TKIs) such as sorafenib, sunitinib, pazopanib and axitinib.https://doi.org/10.1515/fco-2015-0017sunitinibmetastasisrenal cell carcinomatargeted agents |
| spellingShingle | El-Hadaad Hend Ahmed Wahba Hanan Ahmed Abd-El Hay Ghazy Hayam Fathy Metastatic Renal Cell Carcinoma: Sunitinib as First-Line Treatment; Results of a Retrospective Study Forum of Clinical Oncology sunitinib metastasis renal cell carcinoma targeted agents |
| title | Metastatic Renal Cell Carcinoma: Sunitinib as First-Line Treatment; Results of a Retrospective Study |
| title_full | Metastatic Renal Cell Carcinoma: Sunitinib as First-Line Treatment; Results of a Retrospective Study |
| title_fullStr | Metastatic Renal Cell Carcinoma: Sunitinib as First-Line Treatment; Results of a Retrospective Study |
| title_full_unstemmed | Metastatic Renal Cell Carcinoma: Sunitinib as First-Line Treatment; Results of a Retrospective Study |
| title_short | Metastatic Renal Cell Carcinoma: Sunitinib as First-Line Treatment; Results of a Retrospective Study |
| title_sort | metastatic renal cell carcinoma sunitinib as first line treatment results of a retrospective study |
| topic | sunitinib metastasis renal cell carcinoma targeted agents |
| url | https://doi.org/10.1515/fco-2015-0017 |
| work_keys_str_mv | AT elhadaadhendahmed metastaticrenalcellcarcinomasunitinibasfirstlinetreatmentresultsofaretrospectivestudy AT wahbahananahmed metastaticrenalcellcarcinomasunitinibasfirstlinetreatmentresultsofaretrospectivestudy AT abdelhayghazyhayamfathy metastaticrenalcellcarcinomasunitinibasfirstlinetreatmentresultsofaretrospectivestudy |